IP Library Patent Application 17452786
Patent Application
App. No. 17/452,786

1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/452,786
Abstract

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R a , R 1 , R 2 , R 3 , R 4 , R 6 , w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Claims (87)

1 . A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

A is

m is 0, 1, or 2;

n1 is 1, 2, or 3;

R is —H or C 1 -C 3 alkyl;

R a is —H or C 1 -C 3 alkyl;

R 1 , R 2 , R 3 , and R 4 are independently —H, halo, —OH, —NH 2 , C 1 -C 3 alkyl, —OR 7 , —NHR 7 , —N(R 7 )R 7 , —CN, phenyl, or 5- or 6-membered heteroaryl, wherein:

each instance of R 7 independently is unsubstituted C 1 -C 2 alkyl or C 1 -C 2 alkyl substituted with 1-3 halo,

each instance of C 1 -C 3 alkyl independently is unsubstituted or substituted with 1-3 halo, and

the phenyl or heteroaryl is unsubstituted or substituted with 1 or 2 groups independently selected from halo, —OH, —OCH 3 , —OCF 3 , —NH 2 , —NH(CH 3 ), —N(CH 3 ) 2 , —CH 3 , ethyl, —CF 3 , and —CN,

optionally wherein

two adjacent instances of R 1 , R 2 , R 3 , and R 4 together form —O—CH 2 —O—, —O—CH(CH 3 )—O—, —O—C(CH 3 ) 2 —O—, —O—CH 2 —CH 2 —O—, or —O—C(CH 3 ) 2 —C(CH 3 ) 2 —O—;

each instance of R 5 independently is halo, —CH 3 , or ethyl;

each instance of R 6 independently is halo, —CH 3 , ethyl or —OH; and

w is 0, 1, or 2.

2 . The compound of claim 1 of formula (III):

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 2 of formula (IIIa), formula (IIIb), formula (IIIc), or formula (IIId):

or a pharmaceutically acceptable salt thereof.

4 - 11 . (canceled)

12 . The compound of claim 1 of formula (I-C):

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 1.

14 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 2.

15 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n1 is 3.

16 . (canceled)

17 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least three of R 1 , R 2 , R 3 , and R 4 are —H.

18 - 20 . (canceled)

21 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein two adjacent instances of R 1 , R 2 , R 3 , and R 4 together form —O—CH 2 —O—, —O—CH(CH 3 )—O—, or —O—C(CH 3 ) 2 —O—.

22 . (canceled)

23 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a is —H and/or wherein R is —H.

24 - 27 . (canceled)

28 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0 and/or w is 0.

29 - 31 . (canceled)

32 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are independently —H, —F, —CH 3 , —OCH 3 , or —CN.

33 - 36 . (canceled)

37 . The compound of claim 17 , or a pharmaceutically acceptable salt thereof, wherein:

n1 is 2;

R a is H;

m is 0;

w is 0;

R is H; and

R 1 , R 2 , R 3 , and R 4 are independently —H, —F, —CH 3 , —OCH 3 , or —CN.

38 . The compound of claim 1 , selected from those depicted in Table 1:

TABLE 1

I-79

I-80

I-81

I-82

I-83

I-84

I-85

I-86

I-87

I-88

I-89

I-90

I-91

I-92

I-93

I-94

I-95

I-96

I-114

I-115

I-116

I-117

I-126

I-127

I-128

I-133

I-135

I-136

I-143

I-144

or a pharmaceutically acceptable salt thereof.

39 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

40 . The compound of claim 39 , selected from:

or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

41 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

42 . The compound of claim 45 , selected from:

or a pharmaceutically acceptable salt thereof, or a mixture of two or more thereof.

43 . A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

44 . A method for treating a neurological or psychiatric disorder in a patient, comprising administering to said patient an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Oct 31, 2023
From: SUNOVION PHARMACEUTICALS INC.; SUMITOMO PHARMA AMERICA, INC.
To: SUMITOMO PHARMA AMERICA, INC.
Reel/Frame 065400/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: ALEXANDROV, VADIM; HANANIA, TALEEN G.
To: PGI DRUG DISCOVERY LLC
Reel/Frame 057957/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: XIE, LINGHONG; SPEAR, KERRY L.; POWELL, NOEL AARON; JONES, PHILIP GLYN
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 057957/0496 →